Anti-Human Flt-1 / VEGFR-1, bt (AB-FXD) Monoclonal Antibody

Please log in to see the special conditions of your institution.

Synonyms

vascular endothelial growth factor receptor-1, FLT1, VEGF receptor 1

Description of Anti-Human Flt-1 / VEGFR-1, bt (AB-FXD)

Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Biological Activity

ELISA: Use at 1–10 µg/ml; Western blotting: Use at 2–5 µg/ml; FC: Use at 2-10 µg/ml

Reconstitution

Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.

Shipped at room temperature